164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results.
In: Annals of Oncology, Jg. 31 (2020-09-02), S. S306
Online
academicJournal
Zugriff:
Titel: |
164MO Impaired Ki67 response towards neoadjuvant endocrine therapy in luminal breast cancer is associated with mutations conferring endocrine resistance: WSG-ADAPT HR+/HER2- translational results.
|
---|---|
Autor/in / Beteiligte Person: | Grote, I. ; Bartels, S. ; Kandt, L. ; Bollmann, L. ; Christgen, H. ; Gronewold, M. ; Gluz, O. ; Nitz, U. ; Kümmel, S. ; Braun, M. ; Aktas, B. ; Grischke, E M. ; Schumacher, C. ; Lüdtke-Heckenkamp, K. ; Kates, R. ; Wuerstlein, R. ; Gräser, M. ; Harbeck, N. ; Christgen, M. ; Kreipe, H. |
Link: | |
Zeitschrift: | Annals of Oncology, Jg. 31 (2020-09-02), S. S306 |
Veröffentlichung: | 2020 |
Medientyp: | academicJournal |
ISSN: | 0923-7534 (print) |
DOI: | 10.1016/j.annonc.2020.08.286 |
Schlagwort: |
|
Sonstiges: |
|